Acadia Pharmaceuticals (ACAD) said Tuesday in a regulatory filing that 2025 net sales are expected to exceed $1 billion, consistent with prior guidance.

Analysts polled by FactSet expect $1.08 billion.

In a statement, the company projected 2028 sales of $1.7 billion as part of business updates presented at the JPMorgan Healthcare Conference in San Francisco.

Analysts polled by FactSet expect $1.48 billion.